Abstract
AbstractLiquid biopsy represents a new frontier of cancer diagnosis and prognosis, which allows the isolation of tumor cells released in the blood stream. The extremely low abundance of these cells needs appropriate methodologies for their identification and enumeration. Herein we present a new protocol based on surface enhanced resonance Raman scattering (SERRS) gold multivalent nanostructures to identify and enumerate tumor cells with epithelial and mesenchimal markers. The validation of the protocol is obtained with spiked samples of peripheral blood mononuclear cells (PBMC). Gold nanostructures are functionalized with SERRS labels and with antibodies to link the tumor cells. Three types of such nanosystems were simultaneously used and the protocol allows obtaining the identification of all individual tumor cells with the help of a Random Forest ensemble learning method.
Funder
Ministry of Education, University and Research | Instituto Nazionale di Fisica Nucleare
Associazione Italiana per la Ricerca sul Cancro
Ministry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute
Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona
Università degli Studi di Padova
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Di Meo, A., Bartlett, J., Cheng, Y. F., Pasic, M. D. & Yousef, G. M. Liquid biopsy: A step forward towards precision medicine in urologic malignancies. Mol. Cancer https://doi.org/10.1186/s12943-017-0644-5 (2017).
2. Plaks, V., Koopman, C. D. & Werb, Z. Circulating tumor cells. Science 341, 1186–1188. https://doi.org/10.1126/science.1235226 (2013).
3. Ashworth, T. R. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 14, 146–149 (1869).
4. Clare, S. E. et al. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann. Surg. Oncol. 4, 447–451 (1997).
5. Braun, S. et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 342, 525–533 (2000).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献